Welcome to our dedicated page for ORGANON & news (Ticker: OGN), a resource for investors and traders seeking the latest updates and insights on ORGANON & stock.
Organon & Co. reports developments as a global healthcare company with portfolios in Women's Health and General Medicines, including biosimilars. Company news commonly covers operating results, product and regulatory updates, and clinical data for medicines such as VTAMA cream for atopic dermatitis and plaque psoriasis, biosimilar approvals including POHERDY, and established women's health brands and devices such as Nexplanon, Follistim, and Jada.
Updates also address capital-structure disclosures, governance matters, shareholder voting topics, and material agreements, alongside the company's commercial activity across more than 140 markets.
Organon (NYSE: OGN) announced a research collaboration and exclusive license agreement with Cirqle Biomedical to develop a novel non-hormonal contraceptive. This investigational candidate aims to address the unmet needs of women seeking non-hormonal options. Organon will obtain exclusive rights to develop and commercialize the product, with Cirqle receiving a $10 million upfront payment and potential milestone payments of up to $360 million. The collaboration aligns with Organon’s focus on innovation in women’s health, as highlighted by its commitment to new contraceptive solutions.
Organon (NYSE: OGN) will release its second quarter 2022 financial results on August 4, 2022, prior to a conference call scheduled for 8:30 a.m. EDT. The call will be accessible via webcast on the company's website, and a replay will be available two hours post-event. Organon focuses on women's healthcare with over 60 medicines and products in its portfolio. The company aims to improve women's health through innovation and partnerships in growing international markets.
Cognizant (NASDAQ: CTSH) has entered a multi-year agreement with Organon (NYSE: OGN) to enhance the delivery of healthcare products and improve supply chain management. The partnership involves providing industrial technology support at Organon's manufacturing sites across the UK, Netherlands, Belgium, and Indonesia, utilizing SAP's S4/HANA suite. This collaboration aims to boost manufacturing efficiency, increase medicinal yields, and reduce cycle times, facilitating faster access to vital therapies for women's health.
Organon (NYSE: OGN) has announced a licensing agreement with Shanghai Henlius Biotech for the commercialization of biosimilars referencing Perjeta® (HLX11) and Prolia®/Xgeva® (HLX14). This collaboration reinforces Organon's commitment to expanding its biosimilars portfolio, particularly in women's health, focusing on treatments for breast cancer and osteoporosis. The deal includes a $73 million upfront payment and milestone payments based on achievements. This strategy aligns with Organon's goal to enhance patient access to these critical therapies.
Summary not available.
Organon reported first quarter 2022 revenue of $1,567 million, a 4% increase from the previous year. Net income from continuing operations was $348 million or $1.36 per diluted share, reflecting a 12% decline year-over-year. The company’s adjusted net income was $420 million or $1.65 per diluted share, down 7%. Organon continues to grow its women's health offerings and affirmed its full-year financial guidance. A quarterly dividend of $0.28 was declared, payable on June 16, 2022.
Organon (NYSE: OGN) will release its Q1 2022 financial results on May 5, 2022, before an 8:30 a.m. EDT conference call. The call will be accessible via webcast on the company's website, with a replay available approximately two hours later. Analysts and investors must register in advance using conference ID# 6895016. Formed as a spin-off from Merck (NYSE: MRK), Organon focuses on women's health, boasting a diverse portfolio of over 60 medicines. The company aims to collaborate with biopharmaceutical innovators while maintaining strong cash flows for future growth.
Organon (NYSE: OGN) and Daré Bioscience (NASDAQ: DARE) have entered an agreement for Organon to license global rights to XACIATO, an FDA-approved treatment for bacterial vaginosis (BV) affecting an estimated 21 million U.S. women. The deal includes a $10 million upfront payment to Daré, potential milestone payments of up to $182.5 million, and tiered royalties on net sales. XACIATO is expected to be commercially available in the U.S. in Q4 2022, pending regulatory review. This collaboration aligns with Organon's strategy to enhance women's healthcare options.
Organon (NYSE: OGN) announced that CEO Kevin Ali and CFO Matthew Walsh will participate in a fireside chat at the Cowen 42nd Annual Healthcare Virtual Conference on Wednesday, March 9, 2022, at 9:10 a.m. EST. A live video webcast of the event will be accessible for investors, analysts, media, and the public. Organon, a global healthcare company formed from a Merck spin-off, focuses on women's health with a diverse portfolio of over 60 products. The company aims to innovate and partner with biopharmaceutical innovators, leveraging its significant global presence.
Organon (NYSE: OGN) has appointed Meghan Rivera as the new US Managing Director, bringing over 20 years of experience in biopharmaceuticals and digital therapeutics. Ms. Rivera will lead the company's US Commercial Operations team, consisting of 400 staff, aiming to capitalize on growth in women's health, biosimilars, and established brands. Previously, she held key roles at Akili Interactive and AMAG Pharmaceuticals. Organon, a company spun off from Merck (NYSE: MRK), has a strong portfolio of over 60 products focused on women's health, supported by solid cash flows for innovation and growth.